Entheon Biomedical Inc.

CSE: ENBI

Company Logo

Company Overview

Entheon Biomedical Corp. is a psychedelic-drug development company focused on treating substance-use disorder. In particular, the company is committed to the legal development of safe and effective psychedelic medicines, and in educating the public and medical profession as to the efficacy of psychedelic protocols when clinically administered in the optimum set and setting.

Aware of the growing crisis of substance-use disorder and overdose all over the world, Entheon is developing a DMT therapeutic protocol that will be specifically tailored to address the core mechanisms underlying drug-seeking and using behavior. The company's chief aim is to provide an effective and scalable therapeutic protocol that will serve as a vital resource for those afflicted with a substance-use disorder who are wanting to reclaim their lives.

Financial Highlights

$7,356

Revenue (ttm)

$0

Gross Profit (ttm)

-$0.22

Diluted EPS (ttm)

Management Team

Mr. Timothy Ko
Pres, CEO & Director

Mr. Brandon Schwabe CPA, CGA
Chief Financial Officer

Dr. Andrew Peter Hegle Ph.D.
Chief Science Officer, Director of Operations & Director

Dr. Brian E. Jahns Pharm.D.
Chief Bus. Officer

Ms. Kelly Pladson
Corp. Sec.

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$21,216,985

Shares Outstanding
52,320,271

Shares Short (% of Float)
()

Insider Ownership
12%